NCT01608555View on ClinicalTrials.gov

Tobramycin 300 mg Once-a-day (o.d.) Aerosol in Adults With Cystic Fibrosis

PHASE4CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

January 31, 2012

Primary Completion Date

July 31, 2012

Study Completion Date

July 31, 2012

Conditions
Cystic Fibrosis
Interventions
DRUG

tobramycin

inhaled tobramycin 300 mg single dose OD for 28 days

Trial Locations (1)

20122

IRCCS Ospedale Maggiore Policlinico via F. Sforza 35, Milan

All Listed Sponsors
collaborator

Chiesi Farmaceutici S.p.A.

INDUSTRY

lead

University of Milan

OTHER

NCT01608555 - Tobramycin 300 mg Once-a-day (o.d.) Aerosol in Adults With Cystic Fibrosis | Biotech Hunter | Biotech Hunter